E-LIB Suche - Ergebnisse für: Hosoya, Kazutaka

1

Adaptive resistance to lorlatinib via EGFR signaling in ALK..:

Katayama, Yuki ; Yamada, Tadaaki ; Tanimura, Keiko...
npj Precision Oncology. 7 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

2

Author Correction: Survival impact of treatment for chronic..:

Ajimizu, Hitomi ; Ozasa, Hiroaki ; Sato, Susumu...
Scientific Reports. 13 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

3

Yes‐associated protein 1 mediates initial cell survival dur..:

Yamazoe, Masatoshi ; Ozasa, Hiroaki ; Tsuji, Takahiro...
Cancer Science. 114 (2022) 2 - p. 546-560 , 2022

Link: https://doi.org/10.1111/..

4

Classification and regression tree for estimating predictiv..:

Tamiya, Motohiro ; Fujikawa, Kei ; Suzuki, Hidekazu...
Investigational New Drugs. 40 (2022) 2 - p. 361-369 , 2022

Link: https://doi.org/10.1007/..

5

Dissociated response and clinical benefit in patients treat..:

Sato, Yuki ; Morimoto, Takeshi ; Hara, Shigeo...
Investigational New Drugs. 39 (2021) 4 - p. 1170-1178 , 2021

Link: https://doi.org/10.1007/..

6

Survival impact of treatment for chronic obstructive pulmon..:

Ajimizu, Hitomi ; Ozasa, Hiroaki ; Sato, Susumu...
Scientific Reports. 11 (2021) 1 - p. , 2021

Link: https://doi.org/10.1038/..

7

Clinical factors associated with shorter durable response, ..:

Hosoya, Kazutaka ; Fujimoto, Daichi ; Morimoto, Takeshi...
BMC Cancer. 21 (2021) 1 - p. , 2021

Link: https://doi.org/10.1186/..

8

PD-L1 polymorphisms predict survival outcomes in advanced n..:

Yoshida, Hironori ; Nomizo, Takashi ; Ozasa, Hiroaki...
European Journal of Cancer. 144 (2021) - p. 317-325 , 2021

Link: https://doi.org/10.1016/..

9

Association Between Early Immune-related Adverse Events and..:

Hosoya, Kazutaka ; Fujimoto, Daichi ; Morimoto, Takeshi...
Clinical Lung Cancer. 21 (2020) 4 - p. e315-e328 , 2020

Link: https://doi.org/10.1016/..

10

Tumour content ratio matters for detecting epidermal growth..:

Kogo, Mariko ; Fujimoto, Daichi ; Hosoya, Kazutaka...
BMC Cancer. 20 (2020) 1 - p. , 2020

Link: https://doi.org/10.1186/..

11

Efficacy and safety of pembrolizumab as first-line therapy ..:

Tamiya, Motohiro ; Tamiya, Akihiro ; Hosoya, Kazutaka...
Investigational New Drugs. 37 (2019) 6 - p. 1266-1273 , 2019

Link: https://doi.org/10.1007/..

12

Early depth of tumor shrinkage and treatment outcomes in no..:

Kawachi, Hayato ; Fujimoto, Daichi ; Morimoto, Takeshi...
Investigational New Drugs. 37 (2019) 6 - p. 1257-1265 , 2019

Link: https://doi.org/10.1007/..

13

Association between metastatic sites and first-line pembrol..:

Kawachi, Hayato ; Tamiya, Motohiro ; Tamiya, Akihiro...
Investigational New Drugs. 38 (2019) 1 - p. 211-218 , 2019

Link: https://doi.org/10.1007/..

14

Osimertinib in a patient with non-small cell lung cancer an..:

Matsunashi, Atsushi ; Fujimoto, Daichi ; Hosoya, Kazutaka...
Investigational New Drugs. 38 (2019) 4 - p. 1192-1195 , 2019

Link: https://doi.org/10.1007/..

15

Ineligibility for the PACIFIC trial in unresectable stage I..:

Hosoya, Kazutaka ; Fujimoto, Daichi ; Kawachi, Hayato...
Cancer Chemotherapy and Pharmacology. 84 (2019) 2 - p. 275-280 , 2019

Link: https://doi.org/10.1007/..